HMBD-001

Data highlights potential of Hummingbird Bioscience’s dual-payload antibody-drug conjugate platform to improve upon the current generation of ADCs SAN FRANCISCO and SINGAPORE, May 13, 2024 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced two presentations at the 20th Annual PEGS Boston summit being held from May 13-17, 2024. Data from the first presentation demonstrates the ability to direct antibodies and antibody-drug conjugates (ADCs) to rationally selected epitopes of interest on challenging disease-associated proteins. Data from the second presentation show how a novel dual-payload ADC approach has the potential to address resistance and improve the therapeutic window of ADCs. “The data presented at PEGS show for the first time how our proprietary fourth generation antibody-drug conjugate (ADC) platform leverages novel linker and dual-payload technologies to overcome the resistance observed with earlier generation single payload ADCs. Our ADC technology has the potential to treat a large number of patients that have either intrinsic or acquired resistance to currently approved ADCs,” said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. “We will also showcase how our proprietary Rational Antibody Discovery platform engineers immune responses in transgenic mice models so that resulting ADCs and antibodies bind to the key epitopes on disease-associated proteins for optimal drug properties. These data continue to support our belief that our next-generation ADC platform can generate best-in-class ADCs that address payload resistance, optimize tumor specificity, and enhance payload delivery, and therefore maximize the anti-tumor potential of ADCs.” Presentation details: Title: Engineering Immune Responses for Epitope-Focused Antibody Discovery Presenter: Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer Session: Display of Biologics - Novel Platforms Date/Time: Monday, May 13, 2024, 1:45 p.m. ET Title: Overcoming Payload Resistance with Dual-Payload ADCs Presenter: Ben Ayers, DPhil, Vice President, Antibody-Drug Conjugates Session: Driving Clinical Success in Antibody Drug Conjugates - Novel payloads and MOAs Date/Time: Friday, May 17, 2024, 9:30 a.m. ET About Hummingbird Bioscience’s ADC Platform The 4th generation ADC platform developed by Hummingbird Bioscience aims to address the key limitations in efficacy and safety of current approved ADCs. The ADC platform combines the company’s AI-enabled Rational Antibody Discovery Platform and proprietary linker and dual-payload technologies to unlock the power of dual-payload approaches against the most important disease-associated proteins. The platform engineers potentially best-in-class ADCs that address payload resistance, optimize payload delivery and tumor specificity, and maximize anti-tumor cytotoxic potential. About Hummingbird Bioscience’s Rational Antibody Discovery Platform The Rational Antibody Discovery (RAD) platform is designed to address the challenges of traditional antibody approaches. This technology enables the company to identify critical functional regions of a target protein using mAbPredict, a machine learning-enabled technology platform that identifies optimal regions to target, and then drives production of antibodies against these epitopes using mAbHits, a proprietary immuno-engineering technology that directs the antibody response to pre-determined epitopes of interest in the proprietary transgenic HMBD Abvantage mouse. Unlike classical approaches to antibody discovery that have limited control over antibody binding regions, and hence, ability to target optimal epitopes, mAbHits ensures in vivo generation and affinity maturation of antibodies against only the optimal epitope. This systematic and rational approach to antibody discovery opens up the potential of discovering antibodies to specific regions of many important “hard targets” that have not been drugged or are inadequately drugged to date. The RAD platform has produced multiple antibodies and ADCs that effectively target disease-associated proteins, including two antibodies that are currently in Phase I trials (HMBD-001 and HMBD-002) and a recently out-licensed ADC (HMBD-501) that will enter the clinic in 2024. About Hummingbird Bioscience Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. To address key challenges with current antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is building a pipeline of next-generation ADCs using its proprietary antibody discovery and linker/payload platforms. The company has a pipeline of ADCs in preclinical development and other novel biologics including monoclonal antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I and a recently out-licensed ADC (HMBD-501) that will enter the clinic this year. The Hummingbird Bioscience approach combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit , and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. Contacts: Media Crystal Ho c.ho@hummingbirdbio.com media@hummingbirdbio.com +65 6979 5580 Investors investors@hummingbirdbio.com